{"id":40898,"date":"2025-09-08T15:35:24","date_gmt":"2025-09-08T07:35:24","guid":{"rendered":"https:\/\/flcube.com\/?p=40898"},"modified":"2025-09-08T15:35:25","modified_gmt":"2025-09-08T07:35:25","slug":"xwpharma-secures-205-m-valiloxybate-deal-with-avadel","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40898","title":{"rendered":"XWPharma Secures $205\u202fM Valiloxybate Deal with Avadel"},"content":{"rendered":"\n<p>China\u2011based XWPharma Ltd. announced today that it has entered into an exclusive licensing agreement with U.S.\u2011listed Avadel Pharmaceuticals plc (<a href=\"https:\/\/www.google.com\/finance\/quote\/AVDL:NASDAQ\">NASDAQ: AVDL<\/a>). Under the deal, Avadel will develop and commercialize <strong>valiloxybate<\/strong> for all indications in the United States, Europe, and any territory outside mainland China, Hong\u202fKong and Macau.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-strategic-partnership-overview\">Strategic Partnership Overview<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Exclusive Rights<\/strong> \u2013 Avadel obtains sole global rights to valiloxybate, excluding mainland China, Hong\u202fKong, and Macau.<\/li>\n\n\n\n<li><strong>Global Reach<\/strong> \u2013 The agreement covers the U.S., EU, and all other markets, positioning valiloxybate as a worldwide sleep\u2011disorder solution.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-valiloxybate-a-next-generation-oxybate-therapy\">Valiloxybate: A Next\u2011Generation Oxybate Therapy<\/h4>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Once\u2011Nightly Dosing<\/strong><\/td><td>Improves patient adherence compared with twice\u2011daily regimens.<\/td><\/tr><tr><td><strong>Sodium\u2011Free<\/strong><\/td><td>Reduces electrolyte imbalance risks associated with traditional oxybates.<\/td><\/tr><tr><td><strong>Clinical Development<\/strong><\/td><td>Currently in Phase\u202f2\/3 for narcolepsy and idiopathic hypersomnia; potential for broader indications.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-financial-terms-amp-milestone-structure\">Financial Terms &amp; Milestone Structure<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Upfront<\/strong>: $20\u202fM<\/li>\n\n\n\n<li><strong>Development Milestones<\/strong>: Up to $30\u202fM<\/li>\n\n\n\n<li><strong>Sales Milestones<\/strong>: Up to $155\u202fM (tiered)<\/li>\n\n\n\n<li><strong>Royalty Structure<\/strong>:<\/li>\n\n\n\n<li>10\u202f% of annual net sales between $750\u202fM and $3.5\u202fB (performance\u2011based).<\/li>\n\n\n\n<li>Tiered net\u2011sales royalties ranging from high single digits to mid\u2011teens.<\/li>\n\n\n\n<li><strong>FDA\u2011Approval Bonus<\/strong>: Additional $10\u202fM to XWPharma for the first U.S. commercial sale of any new indication beyond narcolepsy and IH.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-regulatory-amp-market-outlook\">Regulatory &amp; Market Outlook<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>U.S. &amp; EU<\/strong>: High regulatory barriers for sleep\u2011disorder therapies; valiloxybate\u2019s sodium\u2011free profile may streamline approval.<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong>: Existing oxybate therapies (e.g., sodium oxybate) face adherence challenges; valiloxybate\u2019s once\u2011nightly dosing could capture substantial market share.<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-implications-for-xwpharma-amp-avadel\">Implications for XWPharma &amp; Avadel<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>XWPharma<\/strong>: Gains significant capital infusion and a long\u2011term revenue stream, enhancing its clinical\u2011stage portfolio.<\/li>\n\n\n\n<li><strong>Avadel<\/strong>: Expands its pipeline in a high\u2011growth sleep\u2011disorder segment, potentially driving shareholder value.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based XWPharma Ltd. announced today that it has entered into an exclusive licensing agreement with&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40901,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4341,4342,4340],"class_list":["post-40898","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-avadel-pharmaceuticals","tag-nasdaq-avdl","tag-xwpharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>XWPharma Secures $205\u202fM Valiloxybate Deal with Avadel - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based XWPharma Ltd. announced today that it has entered into an exclusive licensing agreement with U.S.\u2011listed Avadel Pharmaceuticals plc (Nasdaq:\u202fAVDL). Under the deal, Avadel will develop and commercialize **valiloxybate** for all indications in the United States, Europe, and any territory outside mainland China, Hong\u202fKong and Macau.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40898\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XWPharma Secures $205\u202fM Valiloxybate Deal with Avadel\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40898\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-08T07:35:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-08T07:35:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0810.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40898#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40898\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"XWPharma Secures $205\u202fM Valiloxybate Deal with Avadel\",\"datePublished\":\"2025-09-08T07:35:24+00:00\",\"dateModified\":\"2025-09-08T07:35:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40898\"},\"wordCount\":290,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40898#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0810.webp\",\"keywords\":[\"Avadel Pharmaceuticals\",\"NASDAQ: AVDL\",\"XWPharma\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40898#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40898\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40898\",\"name\":\"XWPharma Secures $205\u202fM Valiloxybate Deal with Avadel - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40898#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40898#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0810.webp\",\"datePublished\":\"2025-09-08T07:35:24+00:00\",\"dateModified\":\"2025-09-08T07:35:25+00:00\",\"description\":\"China\u2011based XWPharma Ltd. announced today that it has entered into an exclusive licensing agreement with U.S.\u2011listed Avadel Pharmaceuticals plc (Nasdaq:\u202fAVDL). Under the deal, Avadel will develop and commercialize **valiloxybate** for all indications in the United States, Europe, and any territory outside mainland China, Hong\u202fKong and Macau.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40898#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40898\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40898#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0810.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0810.webp\",\"width\":1080,\"height\":608,\"caption\":\"XWPharma Secures $205\u202fM Valiloxybate Deal with Avadel\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40898#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XWPharma Secures $205\u202fM Valiloxybate Deal with Avadel\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"XWPharma Secures $205\u202fM Valiloxybate Deal with Avadel - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2011based XWPharma Ltd. announced today that it has entered into an exclusive licensing agreement with U.S.\u2011listed Avadel Pharmaceuticals plc (Nasdaq:\u202fAVDL). Under the deal, Avadel will develop and commercialize **valiloxybate** for all indications in the United States, Europe, and any territory outside mainland China, Hong\u202fKong and Macau.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40898","og_locale":"en_US","og_type":"article","og_title":"XWPharma Secures $205\u202fM Valiloxybate Deal with Avadel","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=40898","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-08T07:35:24+00:00","article_modified_time":"2025-09-08T07:35:25+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0810.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40898#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40898"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"XWPharma Secures $205\u202fM Valiloxybate Deal with Avadel","datePublished":"2025-09-08T07:35:24+00:00","dateModified":"2025-09-08T07:35:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40898"},"wordCount":290,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40898#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0810.webp","keywords":["Avadel Pharmaceuticals","NASDAQ: AVDL","XWPharma"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40898#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40898","url":"https:\/\/flcube.com\/?p=40898","name":"XWPharma Secures $205\u202fM Valiloxybate Deal with Avadel - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40898#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40898#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0810.webp","datePublished":"2025-09-08T07:35:24+00:00","dateModified":"2025-09-08T07:35:25+00:00","description":"China\u2011based XWPharma Ltd. announced today that it has entered into an exclusive licensing agreement with U.S.\u2011listed Avadel Pharmaceuticals plc (Nasdaq:\u202fAVDL). Under the deal, Avadel will develop and commercialize **valiloxybate** for all indications in the United States, Europe, and any territory outside mainland China, Hong\u202fKong and Macau.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40898#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40898"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40898#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0810.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0810.webp","width":1080,"height":608,"caption":"XWPharma Secures $205\u202fM Valiloxybate Deal with Avadel"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40898#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"XWPharma Secures $205\u202fM Valiloxybate Deal with Avadel"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0810.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40898","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40898"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40898\/revisions"}],"predecessor-version":[{"id":40902,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40898\/revisions\/40902"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40901"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40898"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40898"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40898"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}